NCT04438057View on ClinicalTrials.gov

Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

CCP

Randomized open label study to receive 2:1 CCP to standard of care

Trial Locations (1)

60527

Metro Infectious Disease Consultants, Burr Ridge

All Listed Sponsors
lead

Metro Infectious Disease Consultants

OTHER

NCT04438057 - Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 | Biotech Hunter | Biotech Hunter